Assess risk in febrile neutropenia and appropriateness for outpatient management
The Multinational Association for Supportive Care in Cancer (MASCC) Risk Index can be used to identify low-risk patients (score ≥ 21 points) for serious complications of febrile neutropenia (including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications).
The MASCC study was an international collaboration to derive and validate a scoring system to identify low-risk patients for complications of febrile neutropenia.
The score was developed to select patients for therapeutic strategies that could potentially be more convenient or cost-effective. Prospective studies evaluating the use of the MASCC score to identify patients that can be managed with early oral antibiotics or out-of-hospital are ongoing.
A previous scoring system reported by Talcott et al. has also been used to identify low-risk patients that can be successfully treated as outpatients with intravenous or oral antibiotics. The MASCC score has compared favorably with the Talcott score with fewer misclassifications of low-risk patients and improved sensitivity.
Initial pilot studies using the MASCC score to define strategies for low-risk patients have been completed.
Klatersky et al.
Talcott et al.
Klatersky et al.
Freifeld AG, Bow EJ, Sepkowitz KA, et. al.
The Multinational Association for Supportive Care in Cancer (MASCC) Risk Index can be used to identify low-risk patients (score ≥ 21 points) for serious complications of febrile neutropenia (including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications).
The MASCC study was an international collaboration to derive and validate a scoring system to identify low-risk patients for complications of febrile neutropenia.
The score was developed to select patients for therapeutic strategies that could potentially be more convenient or cost-effective. Prospective studies evaluating the use of the MASCC score to identify patients that can be managed with early oral antibiotics or out-of-hospital are ongoing.
A previous scoring system reported by Talcott et al. has also been used to identify low-risk patients that can be successfully treated as outpatients with intravenous or oral antibiotics. The MASCC score has compared favorably with the Talcott score with fewer misclassifications of low-risk patients and improved sensitivity.
Initial pilot studies using the MASCC score to define strategies for low-risk patients have been completed.
Klatersky et al.
Talcott et al.
Klatersky et al.
Freifeld AG, Bow EJ, Sepkowitz KA, et. al.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.